DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)

Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a test-and-treat strategy. Background: Our object...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidalgo-Tenorio, Carmen, Pasquau, Juan, Vinuesa, David, Ferra, Sergio, Terrón, Alberto, SanJoaquín, Isabel, Payeras, Antoni, Martínez, Onofre Juan, López-Ruz, Miguel Ángel, Omar, Mohamed, de la Torre-Lima, Javier, López-Lirola, Ana, Palomares, Jesús, Blanco, José Ramón, Montero, Marta, García-Vallecillos, Coral
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951045/
https://www.ncbi.nlm.nih.gov/pubmed/35336931
http://dx.doi.org/10.3390/v14030524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951045/
https://www.ncbi.nlm.nih.gov/pubmed/35336931
http://dx.doi.org/10.3390/v14030524

Ejemplares similares